{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T14:24:40Z","timestamp":1780755880779,"version":"3.54.1"},"reference-count":76,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Tuftsin, a tetrapeptide (Thr-Lys-Pro-Arg), acts as an immunopotentiating molecule with\nits ability to bind and activate many immune cells, including macrophages or monocytes, neutrophils\nand dendritic cells. The specific targeting activity of tuftsin has been further increased by\nits palmitoylation followed by its incorporation into the lipid bilayer of liposomes. Tuftsin-bearing\nliposomes (Tuft-liposomes) possess several characteristics that enable them to act as a potential\ndrug and vaccine carriers. Tuft-liposomes-loaded anti-microbial drugs have been shown to be highly\neffective against many infectious diseases, including tuberculosis, leishmaniasis, malaria, candidiasis\nand cryptococosis. Moreover, Tuft-liposomes also increased the activity of anticancer drug\netoposide against fibrosarcoma in mice. Tuft-liposomes showed the immune-potentiating effect\nand rejuvenated the immune cells in the leukopenic mice. In addition, antigens encapsulated in\nTuftsin-bearing liposomes demonstrated greater immunogenicity by increasing the T cell proliferation\nand antibody secretion. Keeping into consideration their specific targeting and immunopotentiating\neffects, Tuft-liposomes may potentially be used as promising drug and vaccine delivery systems.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450121999201125200756","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T04:51:50Z","timestamp":1606452710000},"page":"770-778","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the Treatment of Infectious Diseases and Tumors"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-4189","authenticated-orcid":true,"given":"Masood Alam","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah,Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1248\/bpb.b16-00624","volume":"40","author":"Abu Lila A.S.","year":"2017","unstructured":"Abu Lila A.S.; Ishida T.; Liposomal delivery systems: Design optimization and current applications. Biol Pharm Bull 2017,40(1),1-10","journal-title":"Biol Pharm Bull"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/2051013614541440","volume":"2","author":"Schwendener R.A.","year":"2014","unstructured":"Schwendener R.A.; Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines 2014,2(6),159-182","journal-title":"Ther Adv Vaccines"},{"key":"ref=3","first-page":"85","volume":"343","author":"Papahadjopoulos D.","year":"1990","unstructured":"Papahadjopoulos D.; Gabizon A.; Liposomes designed to avoid the reticuloendothelial system. Prog Clin Biol Res 1990,343,85-93","journal-title":"Prog Clin Biol Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ejmech.2019.01.007","volume":"164","author":"Li M.","year":"2019","unstructured":"Li M.; Du C.; Guo N.; Teng Y.; Meng X.; Sun H.; Li S.; Yu P.; Galons H.; Composition design and medical application of liposomes. Eur J Med Chem 2019,164,640-653","journal-title":"Eur J Med Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.4155\/fmc.13.143","volume":"5","author":"Yasinzai M.","year":"2013","unstructured":"Yasinzai M.; Khan M.; Nadhman A.; Shahnaz G.; Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives. Future Med Chem 2013,5(15),1877-1888","journal-title":"Future Med Chem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/j.seminoncol.2004.08.009","volume":"31","author":"Park J.W.","year":"2004","unstructured":"Park J.W.; Benz C.C.; Martin F.J.; Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004,31(6)(Suppl. 13),196-205","journal-title":"Semin Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.tibtech.2013.09.007","volume":"32","author":"Noble G.T.","year":"2014","unstructured":"Noble G.T.; Stefanick J.F.; Ashley J.D.; Kiziltepe T.; Bilgicer B.; Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol 2014,32(1),32-45","journal-title":"Trends Biotechnol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fimmu.2018.00155","volume":"9","author":"Nisini R.","year":"2018","unstructured":"Nisini R.; Poerio N.; Mariotti S.; De Santis F.; Fraziano M.; The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases. Front Immunol 2018,9,155","journal-title":"Front Immunol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.metabol.2017.09.002","volume":"78","author":"Maradana M.R.","year":"2018","unstructured":"Maradana M.R.; Yekollu S.K.; Zeng B.; Ellis J.; Clouston A.; Miller G.; Talekar M.; Bhuyan Z.A.; Mahadevaiah S.; Powell E.E.; Irvine K.M.; Thomas R.; O\u2019Sullivan B.J.; Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis. Metabolism 2018,78,80-94","journal-title":"Metabolism"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/10611869408996811","volume":"2","author":"Bakker-Woudenberg I.A.","year":"1994","unstructured":"Bakker-Woudenberg I.A.; Storm G.; Woodle M.C.; Liposomes in the treatment of infections. J Drug Target 1994,2(5),363-371","journal-title":"J Drug Target"},{"key":"ref=11","first-page":"123","volume":"3","author":"Senior J.H.","year":"1987","unstructured":"Senior J.H.; Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987,3(2),123-193","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=12","first-page":"487","volume":"122","author":"Frank M.M.","year":"1993","unstructured":"Frank M.M.; The reticuloendothelial system and bloodstream clearance. J Lab Clin Med 1993,122(5),487-488","journal-title":"J Lab Clin Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0076-6879(05)91014-8","volume":"391","author":"Bakker-Woudenberg I.A.","year":"2005","unstructured":"Bakker-Woudenberg I.A.; Schiffelers R.M.; Storm G.; Becker M.J.; Guo L.; Long-circulating sterically stabilized liposomes in the treatment of infections. Methods Enzymol 2005,391,228-260","journal-title":"Methods Enzymol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e1900564","DOI":"10.1002\/adhm.201900564","volume":"8","author":"Menina S.","year":"2019","unstructured":"Menina S.; Eisenbeis J.; Kamal M.A.M.; Koch M.; Bischoff M.; Gordon S.; Loretz B.; Lehr C.M.; Bioinspired liposomes for oral delivery of colistin to combat intracellular infections by salmonella enterica. Adv Healthc Mater 2019,8(17),e1900564","journal-title":"Adv Healthc Mater"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1128\/AAC.39.9.2104","volume":"39","author":"Oh Y.K.","year":"1995","unstructured":"Oh Y.K.; Nix D.E.; Straubinger R.M.; Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob Agents Chemother 1995,39(9),2104-2111","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/10611860600720384","volume":"14","author":"Khan M.A.","year":"2006","unstructured":"Khan M.A.; Faisal S.M.; Mohammad O.; Safety, efficacy and pharmacokinetics of tuftsin-loaded nystatin liposomes in murine model. J Drug Target 2006,14(4),233-241","journal-title":"J Drug Target"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/jac\/dkl177","volume":"58","author":"Khan M.A.","year":"2006","unstructured":"Khan M.A.; Owais M.; Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model. J Antimicrob Chemother 2006,58(1),125-132","journal-title":"J Antimicrob Chemother"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1574-695X.2012.00992.x","volume":"66","author":"Khan M.A.","year":"2012","unstructured":"Khan M.A.; Aljarbou A.; Khan A.; Owais M.; Immune stimulating and therapeutic potential of tuftsin-incorporated nystatin liposomes against Cryptococcus neoformans in leukopenic BALB\/C mice. FEMS Immunol Med Microbiol 2012,66(1),88-97","journal-title":"FEMS Immunol Med Microbiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/jac\/dki307","volume":"56","author":"Khan M.A.","year":"2005","unstructured":"Khan M.A.; Nasti T.H.; Owais M.; Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice. J Antimicrob Chemother 2005,56(4),726-731","journal-title":"J Antimicrob Chemother"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.femsim.2004.12.013","volume":"44","author":"Khan M.A.","year":"2005","unstructured":"Khan M.A.; Ahmad N.; Moin S.; Mannan A.; Wajahul H.; Pasha S.T.; Khan A.; Owais M.; Tuftsin-mediated immunoprophylaxis against an isolate of Aspergillus fumigatus shows less in vivo susceptibility to amphotericin B. FEMS Immunol Med Microbiol 2005,44(3),269-276","journal-title":"FEMS Immunol Med Microbiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0196-9781(99)00019-4","volume":"20","author":"Siemion I.Z.","year":"1999","unstructured":"Siemion I.Z.; Kluczyk A.; Tuftsin: on the 30-year anniversary of Victor Najjar\u2019s discovery. Peptides 1999,20(5),645-674","journal-title":"Peptides"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10409238909082550","volume":"24","author":"Fridkin M.","year":"1989","unstructured":"Fridkin M.; Najjar V.A.; Tuftsin: its chemistry, biology, and clinical potential. Crit Rev Biochem Mol Biol 1989,24(1),1-40","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1006861509742","volume":"171","author":"Khare S.","year":"1997","unstructured":"Khare S.; Bhutani L.K.; Rao D.N.; Quantitative assessment of tuftsin receptor expression and second messenger during in vitro differentiation of peripheral blood derived monocytes of leprosy patients. Mol Cell Biochem 1997,171(1-2),1-10","journal-title":"Mol Cell Biochem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.2174\/0929867324666170725140826","volume":"24","author":"Siebert A.","year":"2017","unstructured":"Siebert A.; Gensicka-Kowalewska M.; Cholewinski G.; Dzierzbicka K.; Tuftsin - Properties and Analogs. Curr Med Chem 2017,24(34),3711-3727","journal-title":"Curr Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0169-409X(99)00061-7","volume":"41","author":"Agrawal A.K.","year":"2000","unstructured":"Agrawal A.K.; Gupta C.M.; Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv Drug Deliv Rev 2000,41(2),135-146","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40261-018-0656-y","volume":"38","author":"Plantone D.","year":"2018","unstructured":"Plantone D.; Koudriavtseva T.; Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. Clin Drug Investig 2018,38(8),653-671","journal-title":"Clin Drug Investig"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1128\/AAC.39.1.180","volume":"39","author":"Owais M.","year":"1995","unstructured":"Owais M.; Varshney G.C.; Choudhury A.; Chandra S.; Gupta C.M.; Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium berghei infections in mice. Antimicrob Agents Chemother 1995,39(1),180-184","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S1567-5769(01)00021-2","volume":"1","author":"Dutta R.C.","year":"2001","unstructured":"Dutta R.C.; Puri A.; Anand N.; Immunomodulatory potential of hydrophobic analogs of Rigin and their role in providing protection against Plasmodium berghei infection in mice. Int Immunopharmacol 2001,1(5),843-855","journal-title":"Int Immunopharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0014-5793(89)80222-4","volume":"245","author":"Guru P.Y.","year":"1989","unstructured":"Guru P.Y.; Agrawal A.K.; Singha U.K.; Singhal A.; Gupta C.M.; Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. FEBS Lett 1989,245(1-2),204-208","journal-title":"FEBS Lett"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1128\/IAI.62.6.2649-2652.1994","volume":"62","author":"Cillari E.","year":"1994","unstructured":"Cillari E.; Arcoleo F.; Dieli M.; D\u2019Agostino R.; Gromo G.; Leoni F.; Milano S.; The macrophage-activating tetrapeptide tuftsin induces nitric oxide synthesis and stimulates murine macrophages to kill Leishmania parasites in vitro. Infect Immun 1994,62(6),2649-2652","journal-title":"Infect Immun"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/10611860290007513","volume":"10","author":"Agrawal A.K.","year":"2002","unstructured":"Agrawal A.K.; Agrawal A.; Pal A.; Guru P.Y.; Gupta C.M.; Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J Drug Target 2002,10(1),41-45","journal-title":"J Drug Target"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00436-012-2868-z","volume":"111","author":"Shakya N.","year":"2012","unstructured":"Shakya N.; Sane S.A.; Haq W.; Gupta S.; Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis. Parasitol Res 2012,111(2),563-570","journal-title":"Parasitol Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cyto.2010.04.005","volume":"51","author":"Reljic R.","year":"2010","unstructured":"Reljic R.; Stylianou E.; Balu S.; Ma J.K.; Cytokine interactions that determine the outcome of Mycobacterial infection of macrophages. Cytokine 2010,51(1),42-46","journal-title":"Cytokine"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2217\/nnm.11.122","volume":"6","author":"Pinheiro M.","year":"2011","unstructured":"Pinheiro M.; L\u00facio M.; Lima J.L.; Reis S.; Liposomes as drug delivery systems for the treatment of TB. Nanomedicine (Lond) 2011,6(8),1413-1428","journal-title":"Nanomedicine (Lond)"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1128\/AAC.38.3.588","volume":"38","author":"Agarwal A.","year":"1994","unstructured":"Agarwal A.; Kandpal H.; Gupta H.P.; Singh N.B.; Gupta C.M.; Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice. Antimicrob Agents Chemother 1994,38(3),588-593","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.colsurfb.2018.12.003","volume":"175","author":"Carneiro S.P.","year":"2019","unstructured":"Carneiro S.P.; Carvalho K.V.; de Oliveira Aguiar Soares R.D.; Carneiro C.M.; de Andrade M.H.G.; Duarte R.S.; Dos Santos O.D.H.; Functionalized rifampicin-loaded nanostructured lipid carriers enhance macrophages uptake and antimycobacterial activity. Colloids Surf B Biointerfaces 2019,175,306-313","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1021\/bc500476x","volume":"25","author":"Horv\u00e1ti K.","year":"2014","unstructured":"Horv\u00e1ti K.; Bacsa B.; Kiss E.; Gyulai G.; Fodor K.; Balka G.; Rusvai M.; Szab\u00f3 E.; Hudecz F.; B\u0151sze S.; Nanoparticle encapsulated lipopeptide conjugate of antitubercular drug isoniazid: in vitro intracellular activity and in vivo efficacy in a Guinea pig model of tuberculosis. Bioconjug Chem 2014,25(12),2260-2268","journal-title":"Bioconjug Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00003226-198605030-00012","volume":"5","author":"Smith P.C.","year":"1986","unstructured":"Smith P.C.; Zam Z.S.; Stern G.A.; The effect of tuftsin in the treatment of experimental Pseudomonas keratitis. Cornea 1986,5(3),181-183","journal-title":"Cornea"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1128\/AAC.25.1.134","volume":"25","author":"Blok-Perkowska D.","year":"1984","unstructured":"Blok-Perkowska D.; Muzalewski F.; Konopi\u0144ska D.; Antibacterial properties of tuftsin and its analogs. Antimicrob Agents Chemother 1984,25(1),134-136","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.6004\/jnccn.2004.0036","volume":"2","author":"Cumbo T.A.","year":"2004","unstructured":"Cumbo T.A.; Segal B.H.; Prevention, diagnosis, and treatment of invasive fungal infections in patients with cancer and neutropenia. J Natl Compr Canc Netw 2004,2(5),455-469","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=41","first-page":"1","volume":"32","author":"Stevens D.A.","year":"1995","unstructured":"Stevens D.A.; Therapy for opportunistic fungal infections: past, present and future. Indian J Cancer 1995,32(1),1-9","journal-title":"Indian J Cancer"},{"key":"ref=42","author":"Van Daele R.","year":"2019","unstructured":"Van Daele R.; Spriet I.; Wauters J.; Antifungal drugs: What brings the future? Med Mycol 2019","journal-title":"Med Mycol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/imm.12953","volume":"155","author":"McDermott A.J.","year":"2018","unstructured":"McDermott A.J.; Klein B.S.; Helper T-cell responses and pulmonary fungal infections. Immunology 2018,155(2),155-163","journal-title":"Immunology"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00018-015-1858-6","volume":"72","author":"Swamydas M.","year":"2015","unstructured":"Swamydas M.; Break T.J.; Lionakis M.S.; Mononuclear phagocyte-mediated antifungal immunity: the role of chemotactic receptors and ligands. Cell Mol Life Sci 2015,72(11),2157-2175","journal-title":"Cell Mol Life Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.semdp.2019.04.010","volume":"36","author":"Lockhart S.R.","year":"2019","unstructured":"Lockhart S.R.; Guarner J.; Emerging and reemerging fungal infections. Semin Diagn Pathol 2019,36(3),177-181","journal-title":"Semin Diagn Pathol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1148\/rg.2017160110","volume":"37","author":"Orlowski H.L.P.","year":"2017","unstructured":"Orlowski H.L.P.; McWilliams S.; Mellnick V.M.; Bhalla S.; Lubner M.G.; Pickhardt P.J.; Menias C.O.; Imaging Spectrum of Invasive Fungal and Fungal-like Infections. Radiographics 2017,37(4),1119-1134","journal-title":"Radiographics"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"Allen T.M.","year":"2013","unstructured":"Allen T.M.; Cullis P.R.; Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013,65(1),36-48","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12275-011-1064-7","volume":"49","author":"Kim J.","year":"2011","unstructured":"Kim J.; Sudbery P.; Candida albicans, a major human fungal pathogen. J Microbiol 2011,49(2),171-177","journal-title":"J Microbiol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/1061186031000119093","volume":"11","author":"Khan M.A.","year":"2003","unstructured":"Khan M.A.; Syed F.M.; Nasti H.T.; Saima Dagger K.; Haq W.; Shehbaz A.; Owais M.; Use of tuftsin bearing nystatin liposomes against an isolate of Candida albicans showing less in vivo susceptibility to amphotericin B. J Drug Target 2003,11(2),93-99","journal-title":"J Drug Target"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.femsim.2004.03.011","volume":"41","author":"Khan M.A.","year":"2004","unstructured":"Khan M.A.; Nasti T.H.; Saima K.; Mallick A.I.; Firoz A.; Wajahul H.; Ahmad N.; Mohammad O.; Co-administration of immunomodulator tuftsin and liposomised nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice. FEMS Immunol Med Microbiol 2004,41(3),249-258","journal-title":"FEMS Immunol Med Microbiol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrmicro.2015.6","volume":"14","author":"May R.C.","year":"2016","unstructured":"May R.C.; Stone N.R.; Wiesner D.L.; Bicanic T.; Nielsen K.; Cryptococcus: from environmental saprophyte to global pathogen. Nat Rev Microbiol 2016,14(2),106-117","journal-title":"Nat Rev Microbiol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/QCO.0000000000000458","volume":"31","author":"Henao-Mart\u00ednez A.F.","year":"2018","unstructured":"Henao-Mart\u00ednez A.F.; Chastain D.B.; Franco-Paredes C.; Treatment of cryptococcosis in non-HIV immunocompromised patients. Curr Opin Infect Dis 2018,31(4),278-285","journal-title":"Curr Opin Infect Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2217\/fmb.14.132","volume":"10","author":"Rohatgi S.","year":"2015","unstructured":"Rohatgi S.; Pirofski L.A.; Host immunity to Cryptococcus neoformans. Future Microbiol 2015,10(4),565-581","journal-title":"Future Microbiol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/10611860500403222","volume":"13","author":"Khan M.A.","year":"2005","unstructured":"Khan M.A.; Owais M.; Immunomodulator tuftsin increases the susceptibility of Cryptococcus neoformans to liposomal amphotericin B in immunocompetent BALB\/c mice. J Drug Target 2005,13(7),423-429","journal-title":"J Drug Target"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"6331","DOI":"10.2147\/IJN.S86467","volume":"10","author":"Khan M.A.","year":"2015","unstructured":"Khan M.A.; Aljarbou A.N.; Aldebasi Y.H.; Alorainy M.S.; Khan A.; Combination of glycosphingosomes and liposomal doxorubicin shows increased activity against dimethyl-\u03b1-benzanthracene-induced fibrosarcoma in mice. Int J Nanomedicine 2015,10,6331-6338","journal-title":"Int J Nanomedicine"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3109\/07388551.2015.1015957","volume":"36","author":"Kartal-Yandim M.","year":"2016","unstructured":"Kartal-Yandim M.; Adan-Gokbulut A.; Baran Y.; Molecular mechanisms of drug resistance and its reversal in cancer. Crit Rev Biotechnol 2016,36(4),716-726","journal-title":"Crit Rev Biotechnol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2119\/2007-00018.Khan","volume":"13","author":"Khan A.","year":"2007","unstructured":"Khan A.; Khan A.A.; Dwivedi V.; Ahmad M.G.; Hakeem S.; Owais M.; Tuftsin augments antitumor efficacy of liposomized etoposide against fibrosarcoma in Swiss albino mice. Mol Med 2007,13(5-6),266-276","journal-title":"Mol Med"},{"key":"ref=58","first-page":"264","volume":"9","author":"Chu D.Z.","year":"1990","unstructured":"Chu D.Z.; Nishioka K.; Tuftsin increases survival in murine peritoneal carcinomatosis. J Biol Response Mod 1990,9(2),264-267","journal-title":"J Biol Response Mod"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1099\/0022-1317-67-9-2001","volume":"67","author":"Wleklik M.","year":"1986","unstructured":"Wleklik M.; Levy S.B.; Luczak M.; Najjar V.A.; Suppression of Friend virus-induced leukaemia in mice by tuftsin. J Gen Virol 1986,67(Pt 9),2001-2004","journal-title":"J Gen Virol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0014-5793(84)81251-X","volume":"178","author":"Singhal A.","year":"1984","unstructured":"Singhal A.; Bali A.; Jain R.K.; Gupta C.M.; Specific interactions of liposomes with PMN leukocytes upon incorporating tuftsin in their bilayers. FEBS Lett 1984,178(1),109-113","journal-title":"FEBS Lett"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1007\/BF01919150","volume":"48","author":"Singh S.P.","year":"1992","unstructured":"Singh S.P.; Chhabra R.; Srivastava V.M.; Respiratory burst in peritoneal exudate cells in response to a modified tuftsin. Experientia 1992,48(10),994-996","journal-title":"Experientia"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/10611860412331285215","volume":"12","author":"Khan M.A.","year":"2004","unstructured":"Khan M.A.; Firoz A.; Jabeen R.; Mohammad O.; Prophylactic role of immunomodulators in treatment of systemic candidiasis in leukopenic mice. J Drug Target 2004,12(7),425-433","journal-title":"J Drug Target"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1574-695X.2005.00014.x","volume":"46","author":"Khan M.A.","year":"2006","unstructured":"Khan M.A.; Khan A.; Owais M.; Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice. FEMS Immunol Med Microbiol 2006,46(1),63-69","journal-title":"FEMS Immunol Med Microbiol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/BF00229905","volume":"75","author":"Wleklik M.S.","year":"1987","unstructured":"Wleklik M.S.; Luczak M.; Najjar V.A.; Tuftsin induced tumor necrosis activity. Mol Cell Biochem 1987,75(2),169-174","journal-title":"Mol Cell Biochem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0162-3109(97)00002-7","volume":"37","author":"Granoth R.","year":"1997","unstructured":"Granoth R.; Vadai E.; Burstein Y.; Fridkin M.; Tzehoval E.; Tuftsin-THF-gamma 2 chimeric peptides: potential novel immunomodulators. Immunopharmacology 1997,37(1),43-52","journal-title":"Immunopharmacology"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1365-2249.1990.tb05430.x","volume":"82","author":"Holland G.P.","year":"1990","unstructured":"Holland G.P.; Holland N.; Steward M.W.; Interferon-gamma potentiates antibody affinity in mice with a genetically controlled defect in affinity maturation. Clin Exp Immunol 1990,82(2),221-226","journal-title":"Clin Exp Immunol"},{"key":"ref=67","first-page":"71","volume":"3","author":"Levy R.","year":"1989","unstructured":"Levy R.; Kain Z.; Chaimovitz C.; Fridkin M.; Segal S.; Alkan M.; Potential use of tuftsin in treatment of candida peritonitis in a murine model. J Biol Regul Homeost Agents 1989,3(2),71-78","journal-title":"J Biol Regul Homeost Agents"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/mrd.1120230402","volume":"23","author":"Filippini A.","year":"1989","unstructured":"Filippini A.; Russo M.A.; Palombi F.; Bertalot G.; De Cesaris P.; Stefanini M.; Ziparo E.; Modulation of phagocytic activity in cultured Sertoli cells. Gamete Res 1989,23(4),367-375","journal-title":"Gamete Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/hep.1840190433","volume":"19","author":"Kubo S.","year":"1994","unstructured":"Kubo S.; Rodriguez T.; Roh M.S.; Oyedeji C.; Romsdahl M.M.; Nishioka K.; Stimulation of phagocytic activity of murine Kupffer cells by tuftsin. Hepatology 1994,19(4),1044-1049","journal-title":"Hepatology"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.12659\/MSM.915037","volume":"25","author":"Zou B.","year":"2019","unstructured":"Zou B.; Xia S.; Du X.; Xu Y.; Ning N.; Li S.; Teng D.; Li H.; Hu Z.; Hu S.; Wang Y.; Treatment Effect of Tuftsin and Antigen Peptide Combined with Immune Cells on Colorectal Cancer. Med Sci Monit 2019,25,5465-5472","journal-title":"Med Sci Monit"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/092986613804725299","volume":"20","author":"Wardowska A.","year":"2013","unstructured":"Wardowska A.; Dzierzbicka K.; Menderska A.; Trzonkowski P.; New conjugates of tuftsin and muramyl dipeptide as stimulators of human monocyte-derived dendritic cells. Protein Pept Lett 2013,20(2),200-204","journal-title":"Protein Pept Lett"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"e0123400","DOI":"10.1371\/journal.pone.0123400","volume":"10","author":"Gao Y.","year":"2015","unstructured":"Gao Y.; Su Q.; Yi Y.; Jia Z.; Wang H.; Lu X.; Qiu F.; Bi S.; Enhanced mucosal immune responses induced by a combined candidate mucosal vaccine based on Hepatitis A virus and Hepatitis E virus structural proteins linked to tuftsin. PLoS One 2015,10(4),e0123400","journal-title":"PLoS One"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.1016\/j.vaccine.2012.08.054","volume":"30","author":"Liu X.","year":"2012","unstructured":"Liu X.; Guo J.; Han S.; Yao L.; Chen A.; Yang Q.; Bo H.; Xu P.; Yin J.; Zhang Z.; Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin. Vaccine 2012,30(46),6527-6533","journal-title":"Vaccine"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/10611860290022615","volume":"10","author":"Masood A.K.","year":"2002","unstructured":"Masood A.K.; Faisal S.M.; Haque W.; Owais M.; Immunomodulator tuftsin augments anti-fungal activity of amphotericin B against experimental murine candidiasis. J Drug Target 2002,10(3),185-192","journal-title":"J Drug Target"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/0014-5793(93)81760-W","volume":"326","author":"Owais M.","year":"1993","unstructured":"Owais M.; Ahmed I.; Krishnakumar B.; Jain R.K.; Bachhawat B.K.; Gupta C.M.; Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental aspergillosis. FEBS Lett 1993,326(1-3),56-58","journal-title":"FEBS Lett"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/10611860310001620707","volume":"11","author":"Owais M.","year":"2003","unstructured":"Owais M.; Misra-Bhattacharya S.; Haq W.; Gupta C.M.; Immunomodulator tuftsin augments antifilarial activity of diethylcarbamazine against experimental brugian filariasis. J Drug Target 2003,11(4),247-251","journal-title":"J Drug Target"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450121999201125200756","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/188389\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389450121999201125200756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T06:03:29Z","timestamp":1660716209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/188389\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":76,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450121999201125200756","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}